Observational studyAnnals of hematology2025

Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.

Vania Hungria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.